02.02.11
Hospira 4Q10
4Q Revenues: $992.1 million (-6%)
4Q Earnings: $60.6 million (-37%)
FY Revenues: $3.9 billion (+1%)
FY Earnings: $357.2 million (-12%)
Comments: Global Specialty Injectable Pharmaceuticals sales in the quarter were $605.0 million, (+5%). Sales in the Americas were up 4%, Europe, Middle East & Africa sales were up 1%, and Asia Pacific sales were up 10%. For the year, Global Specialty Injectable Pharmaceuticals sales were $2.3 billion, up 13%. Sales in the Americas were up 15%, Europe, Middle East & Africa sales were up 4%, and Asia Pacific sales were up 12%. Results were impacted by a decline in Medication Management, primarily due to the voluntary hold on shipments of Symbiq Infusion System, and the decline in Other Pharma, as a result of the impact of non-strategic asset divestitures.
4Q Revenues: $992.1 million (-6%)
4Q Earnings: $60.6 million (-37%)
FY Revenues: $3.9 billion (+1%)
FY Earnings: $357.2 million (-12%)
Comments: Global Specialty Injectable Pharmaceuticals sales in the quarter were $605.0 million, (+5%). Sales in the Americas were up 4%, Europe, Middle East & Africa sales were up 1%, and Asia Pacific sales were up 10%. For the year, Global Specialty Injectable Pharmaceuticals sales were $2.3 billion, up 13%. Sales in the Americas were up 15%, Europe, Middle East & Africa sales were up 4%, and Asia Pacific sales were up 12%. Results were impacted by a decline in Medication Management, primarily due to the voluntary hold on shipments of Symbiq Infusion System, and the decline in Other Pharma, as a result of the impact of non-strategic asset divestitures.
